Here are five highlights:
1. The award recognizes the company’s i‑FACTOR Peptide Enhanced Bone Graft.
2. The i‑FACTOR Peptide Enhanced Bone Graft features proprietary biomimetic small peptide technology that promotes osteoblast cell proliferation and differentiation to accelerate new bone formation.
3. The technology is intended for patients suffering from degenerative disc disease.
4. The i-FACTOR technology is the second bone graft to earn premarket approval in spine.
5. An investigational device exemption clinical trial testing the technology revealed supportive safety and efficacy data.
More articles on biologics:
Edison Healthcare offers employees biologic-based alternatives to orthopedic surgery: 3 insights
NuVasive launches AttraX Scaffold biologic: 4 things to know
Spine biologics market to grow at CAGR of 4.09% through 2022
